Abstract
Aim:
The selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors (SNRIs) are commonly used for the treatment of neuropathic pain and fibromyalgia. Ammoxetine ((±)-3-(benzo[d] [1,3]dioxol-4-yloxy)-N-methyl-3-(thiophen-2-yl)propan-1-amine) has been identified as a novel potent SNRI. In this study, we evaluated the acute analgesic properties of ammoxetine in different animal models of pain, and examined the involvement of monoamines in its analgesic actions.
Methods:
The analgesic effects of ammoxetine were assayed using models of acetic acid- and formalin-induced pain in mice, neuropathic pain induced by sciatic nerve injury (SNI), chronic constriction injury (CCI) and reserpine-induced fibromyalgia pain in rats. The contents of 5-HT and NE in brain regions of fibromyalgia rats were measured using HPLC-ECD. In all the experiments, duloxetine was used as a positive control drug.
Results:
Oral administration of ammoxetine (0.625–10 mg/kg) or duloxetine (2.5–40 mg/kg) dose-dependently decreased the number of acetic acid-induced writhing and formalin-induced first phase and second phase paw licking time in mice. Oral administration of ammoxetine (2.5–10 mg/kg) or duloxetine (10 mg/kg) alleviated mechanical allodynia in SNI and CCI rats and thermal hyperalgesia in CCI rats. The antiallodynic effect of ammoxetine in CCI rats was abolished by pretreatment with para-chlorophenylalanine methyl ester hydrochloride (PCPA, a 5-HT synthesis inhibitor) or α-methyl-para-tyrosine methylester (AMPT, a catecholamine synthesis inhibitor). Oral administration of ammoxetine (30 mg/kg) or duloxetine (50 mg/kg) significantly attenuated tactile allodynia in rats with reserpine-induced fibromyalgia. In the fibromyalgia rats, administration of ammoxetine (10, 30 mg/kg) or duloxetine (30, 50 mg/kg) dose-dependently increased the levels of 5-HT and NE, and decreased the metabolite ratio of 5-HT (5-HIAA/5-HT) in the spinal cord, hypothalamus, thalamus and prefrontal cortex.
Conclusion:
Ammoxetine effectively alleviates inflammatory, continuous, neuropathic and fibromyalgia-related pain in animal models, which can be attributed to enhanced neurotransmission of 5-HT and NE in the descending inhibitory systems.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bair MJ, Robinson RL, Katon W, Kroenke K . Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45.
Leo RJ . Chronic pain and comorbid depression. Curr Treat Options Neurol 2005; 7: 403–12.
Cayley WE Jr . Antidepressants for the treatment of neuropathic pain. Am Fam Physician 2006; 73: 1933–4.
Mico JA, Ardid D, Berrocoso E, Eschalier A . Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348–54.
Finnerup NB, Sindrup SH, Jensen TS . The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573–81.
Yarnitsky D . Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain 2015; 156: 24–31.
Thor KB, Kirby M, Viktrup L . Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 2007; 61: 1349–55.
Bannister K, Bee LA, Dickenson AH . Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009; 6: 703–12.
An update on the drug treatment of neuropathic pain. Part 1: antidepressants. Drug Ther Bull 2012; 50: 114–7.
O'Connor AB, Dworkin RH . Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122: 22–32.
Liu WQ, Kanungo A, Toth C . Equivalency of tricyclic antidepressants in open-label neuropathic pain study. Acta Neurol Scand 2014; 129: 132–41.
Anderson IM . Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36.
Lee YC, Chen PP . A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 2010; 11: 2813–25.
Jung AC, Staiger T, Sullivan M . The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997; 12: 384–9.
Dharmshaktu P, Tayal V, Kalra BS . Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012; 52: 6–17.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237–51.
Lunn MP, Hughes RA, Wiffen PJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 1: 1–121.
Watson CP, Gilron I, Sawynok J, Lynch ME . Nontricyclic antidepressant analgesics and pain: are serotonin norepinephrine reuptake inhibitors (SNRIs) any better? Pain 2011; 152: 2206–10.
Smith T, Nicholson RA . Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 2007; 3: 833–44.
Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P . A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 2013; 13: 239–52.
Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871–80.
Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003; 45: 935–44.
Bel N, Artigas F . Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology 1999; 21: 745–54.
Xue R, He XH, Yuan L, Chen HX, Zhang LM, Yong Z, et al. Effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor, on monoamine system in mice and rats. J Pharmacol Sci 2016; 130: 1–7.
Xue R, Jin ZL, Chen HX, Yuan L, He XH, Zhang YP, et al. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. Eur Neuropsychopharmacol 2013; 23: 728–41.
Xue R, Zhang YP, Jin ZL, Yuan L, He XH, Zhao N, et al. The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor. Neurosci Lett 2013; 544: 68–73.
Satyanarayana PS, Jain NK, Singh A, Kulkarni SK . Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 641–9.
Shibata M, Ohkubo T, Takahashi H, Inoki R . Modified formalin test: characteristic biphasic pain response. Pain 1989; 38: 347–52.
Decosterd I, Woolf CJ . Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000; 87: 149–58.
Bennett GJ, Xie YK . A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87–107.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL . Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55–63.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J . A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77–88.
Nagakura Y, Oe T, Aoki T, Matsuoka N . Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 2009; 146: 26–33.
Kaneko K, Umehara M, Homan T, Okamoto K, Oka M, Oyama T . The analgesic effect of tramadol in animal models of neuropathic pain and fibromyalgia. Neurosci Lett 2014; 562: 28–33.
Aoki M, Tsuji M, Takeda H, Harada Y, Nohara J, Matsumiya T, et al. Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice. Eur J Pharmacol 2006; 550: 78–83.
Korzeniewska-Rybicka I, Plaznik A . Analgesic effect of antidepressant drugs. Pharmacol Biochem Behav 1998; 59: 331–8.
Lyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM . Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004; 311: 576–84.
Bardin L, Gregoire S, Aliaga M, Malfetes N, Vitton O, Ladure P, et al. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neurosci Res 2010; 66: 135–40.
Chen HS, Li MM, Shi J, Chen J . Supraspinal contribution to development of both tonic nociception and referred mirror hyperalgesia: a comparative study between formalin test and bee venom test in the rat. Anesthesiology 2003; 98: 1231–6.
Murai N, Aoki T, Tamura S, Sekizawa T, Kakimoto S, Tsukamoto M, et al. AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in a rat model of neuropathic pain with unique characteristics in spinal monoamine turnover. J Pharmacol Exp Ther 2014; 348: 372–82.
Bomholt SF, Mikkelsen JD, Blackburn-Munro G . Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 2005; 48: 252–63.
Le Cudennec C, Castagne V . Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine. Eur J Pharmacol 2014; 735: 17–25.
Prinssen EP, Assie MB, Koek W, Kleven MS . Depletion of 5-HT disrupts prepulse inhibition in rats: dependence on the magnitude of depletion, and reversal by a 5-HT precursor. Neuropsychopharmacology 2002; 26: 340–7.
Ucel UI, Can OD, Demir Ozkay U, Ozturk Y . Antihyperalgesic and antiallodynic effects of mianserin on diabetic neuropathic pain: a study on mechanism of action. Eur J Pharmacol 2015; 756: 92–106.
Corrodi H, Hanson LC . Central effects of an inhibitor of tyrosine hydroxylation. Psychopharmacologia 1966; 10: 116–25.
Wood PB, Holman AJ, Jones KD . Novel pharmacotherapy for fibromyalgia. Expert Opin Investig Drugs 2007; 16: 829–41.
Yunus MB . Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339–56.
Acknowledgements
This work was supported by the National Key New Drug Creation Program (No 2012ZX09102101-004) and the National Natural Science Foundation of China (No 81302761, 81274117, and 30973516).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhang, Tt., Xue, R., Zhu, L. et al. Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor. Acta Pharmacol Sin 37, 1154–1165 (2016). https://doi.org/10.1038/aps.2016.45
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.45
Keywords
This article is cited by
-
Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease
npj Parkinson's Disease (2020)
-
Coexistence of Alterations of Gastrointestinal Function and Mechanical Allodynia in the Reserpine-Induced Animal Model of Fibromyalgia
Digestive Diseases and Sciences (2019)
-
Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord
Journal of Neuroinflammation (2018)
